On July 3, BeiGene rose 3.49% in regular trading, trading at HK$182.1/share, with turnover of HK$130 million.

The rally was driven by continued market enthusiasm over Brukinsa (zanubrutinib) Phase 3 MANGROVE study results disclosed on June 30. The study evaluated Brukinsa plus rituximab versus bendamustine-rituximab for first-line treatment of mantle cell lymphoma, achieving its primary endpoint with a 43% reduction in disease progression or death risk (HR=0.57). The company plans regulatory submissions in the second half of the year.

Additionally, the national medical insurance directory initial review pass rate reached 92%, coupled with the launch of a commercial insurance innovative drug directory mechanism, further optimizing payment channels for innovative drugs. Brokerages including CITIC Construction Investment expressed bullish views on innovative drug companies benefiting from expanded insurance access.

The broader biotechnology sector rallied in tandem, with 3SBio up 5.07%, Remegen up 4.31%, SKB Bio up 3.46%, and Akeso up 3.22%, providing sector-wide support. The prior CNY 446 million tax supplementary payment overhang has been largely absorbed by the market.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)